Corcept Therapeutics (CORT) Short term Debt (2012 - 2017)

Corcept Therapeutics has disclosed Short term Debt across 6 years of filings, most recently posting $4.6 million for Q2 2017.

• Short term Debt for Q2 2017 came in at $4.6 million, down 75.36% year-over-year; the trailing twelve-month figure through Jun 2017 was $4.6 million (down 75.36% YoY), and the FY2016 annual result was $14.7 million, down 2.01% from the prior year.
• Short term Debt came in at $4.6 million for Q2 2017 at Corcept Therapeutics, down from $10.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $18.7 million in Q3 2016 to a low of $3.6 million in Q2 2013.
• The 5-year median for Short term Debt is $9.8 million (2014), against an average of $10.2 million.
• Across the five-year window, Short term Debt surged 116.72% in 2013 and tumbled 75.36% in 2017, its largest moves.
• Corcept Therapeutics' Short term Debt stood at $5.7 million in 2013, then jumped by 64.1% to $9.4 million in 2014, then jumped by 58.8% to $15.0 million in 2015, then decreased by 2.01% to $14.7 million in 2016, then plunged by 68.81% to $4.6 million in 2017.
• The last three Short term Debt figures came in at $4.6 million (Q2 2017), $10.1 million (Q1 2017), and $14.7 million (Q4 2016), per Business Quant data.